Abstract

 One of the daily challenges for health care policy makers is selecting the right patient for the right treatment with affordable price. If we taking breast cancer treatments at law middle income country, as Egypt's experience with breast cancer, an incidence (15.4) per 100,000 beside the prevalence of HER2-positive breast cancer is approximately 15% to 20% of primary breast cancers. this will lead to economic burden as well as consequences on decision makers. When they decides to treat with monoclonal antibodies like Trastuzumab what is the appropriate time to treat the patient to achieve the efficient management of resources 6 months versus 12 months of adjuvant Trastuzumab in early breast cancer. What will be the best option for the resources and patients outcomes? To answer the previous question an economic study was conducted trying to support decisions makers. The result of economic model showed that selecting one clinical study for deciding shorter time regimen versus standard regimen is might not be strong evidence for taking the decisions because the economic model was so sensitive to the following parameters. Selecting data for health care decision making in oncology should take in consideration. Strength of evidence sensitivity analysis of that data should be conducted to ensure effective health care decisions and losing the previous criteria might lead to negative impact on patients’ outcomes and treatment resources.

Keywords: Trastuzumab 6 Months; Health Policy; Reimbursement

References

1. Piccart-Gebhart MJ., et al. “Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer”. New England Journal of Medicine 16 (2005): 1659-1672.
2. Romond EH., et al. “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer”. New England Journal of Medicine 16 (2005): 1673-1684.
3. Slamon D., et al. “Adjuvant trastuzumab in HER2-positive breast cancer”. New England Journal of Medicine 14 (2011): 1273-1283.
4. Joensuu H., et al. “Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer”. New England Journal of Medicine 8 (2006): 809-820.
5. European Medicines Agency. “Committee for medicinal products for human use (CHMP) guideline on the choice of the non-inferiority margin”. Statistics in Medicine 10 (2006): 1628-1638.
6. Smith I., et al. “2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial”. Lancet 9555 (2007): 29-36.
7. Herceptin European Summary of product characteristics (2013).
8. Perez EA., et al. “Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31”. Journal of Clinical Oncology 25 (2011): 3366-3373.
9. Gianni L., et al. “Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial”. Lancet Oncology3 (2011): 236-244.
10. Spielmann M., et al. “Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial”. Journal of Clinical Oncology 36 (2009): 6129-6134.
11. Perez EA., et al. “Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer”. Journal of Clinical Oncology 34 (2011): 4491-4497.
12. Goldhirsch A., et al. “HERA trial: 2 year versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. San Antonio Breast Cancer Symposium 2012”. Cancer Research 24 (2012): abstract S5-2.
13. Piaggio G., et al. “Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement”. Journal of the American Medical Association 10 (2006): 1152-1160.

Citation

Citation: Abdalla Abotaleb. “Effect of Data Selection on Reimbursement Decisions. Breast Cancer Case”. Acta Scientific Women's Health 2.5 (2020): 23-27.

Copyright

Copyright: © 2020 Abdalla Abotaleb. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.